(Dapagliflozin + metoprolol) XR is under clinical development by Eris Lifesciences and currently in Phase III for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase III drugs for Congestive Heart Failure (Heart Failure) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Dapagliflozin + metoprolol) XR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Dapagliflozin + metoprolol) XR overview

A fixed dose combination of dapagliflozin and metoprolol is under development for the treatment of heart failure post-acute myocardial infarction. It is administered through oral route in the form of extended-release tablet. Dapagliflozin acts by targeting sodium-glucose cotransporter2 (SGLT2) and metoprolol acts by targeting beta 1 adrenergic receptor.

Eris Lifesciences overview

Eris Lifesciences (Eris) is a pharmaceutical company. It develops, manufactures, and supplies pharmaceutical formulations to treat chronic and sub-chronic diseases. The company product portfolio includes tablets, capsules, sprays, syrups, drops, powder, injections, cookies, ointments, and soft gels to treat pain, diabetes, cardiovascular, gynic, respiratory, neuroscience and gastrointestinal disorders. Eris also offers vitamins, minerals, and nutrition formulations. The company markets its products under Alerfix, Atorsave F, Axunil, Carpela, Citelec, DeepSenz, Obicure, Glimisave, Tendia, Cyblex, Zomelis, Otogesic, Raricap, Recontrex and other brands. It supplies its products through a network of distributors and chemist outlets across India. The company operates a manufacturing facility in Guwahati, Assam, India. Eris is headquartered in Ahmedabad, Gujarat, India.

For a complete picture of (Dapagliflozin + metoprolol) XR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.